Clinical significance of macrophage heterogeneity in human malignant tumors

Cancer Science - Tập 105 Số 1 - Trang 1-8 - 2014
Yoshihiro Komohara1, Masahisa Jinushi2, Motohiro Takeya1
1Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2Research Center for Infection‐associated Cancer Institute for Genetic Medicine Hokkaido University Sapporo Japan

Tóm tắt

The fact that various immune cells, including macrophages, can be found in tumor tissue has long been known. With the recent introduction of the novel concept of macrophage differentiation into a classically activated phenotype (M1) and an alternatively activated phenotype (M2), the role of tumor‐associated macrophages (TAMs) is gradually beginning to be elucidated. Specifically, in human malignant tumors, TAMs that have differentiated into M2 macrophages act as “protumoral macrophages” and contribute to the progression of disease. Based on recent basic and preclinical research, TAMs that have differentiated into protumoral or M2 macrophages are believed to be intimately involved in the angiogenesis, immunosuppression, and activation of tumor cells. In this paper, we specifically discuss both the role of TAMs in human malignant tumors and the cell–cell interactions between TAMs and tumor cells.

Từ khóa


Tài liệu tham khảo

10.1002/1097-0142(196103/04)14:2<369::AID-CNCR2820140217>3.0.CO;2-X

Underwood JC, 1972, The ultrastructure of the lymphoreticular cells in non‐lymphoid human neoplasms, Virchows Arch B Cell Pathol, 12, 39, 10.1007/BF02893984

10.1136/jcp.30.6.563

Kreutz M, 2002, The Macrophage, 458

Tagliabue A, 1979, Natural cytotoxicity of mouse monocytes and macrophages, J Immunol, 122, 2363, 10.4049/jimmunol.122.6.2363

10.1016/S1471-4906(02)02302-5

10.1002/path.1027

10.1038/nrc1256

10.1186/1479-5876-9-216

10.1002/path.2370

10.1016/j.ejca.2006.01.003

10.1038/nri1995

10.4049/jimmunol.179.5.3332

10.1038/nature07205

10.1189/jlb.1107762

10.1371/journal.pone.0023902

10.1093/jnci/djq044

10.1158/0008-5472.CAN-08-2871

10.1084/jem.20081605

10.1084/jem.193.6.727

10.1189/jlb.0609385

10.1155/2011/565187

10.1111/j.1349-7006.2009.01300.x

10.1038/ncb1794

10.1038/ncb1507

10.1084/jem.176.1.287

10.1016/S1074-7613(00)80014-X

10.1038/nri978

10.1369/jhc.5A6871.2006

10.1016/S0021-9150(01)00624-4

10.1111/j.1349-7006.2009.01296.x

10.4049/jimmunol.1203194

10.4161/onci.19728

10.1111/j.1349-7006.2011.01945.x

10.1111/j.1440-1827.2010.02514.x

10.1111/cas.12167

10.1111/cas.12188

10.1016/j.cell.2010.03.014

10.1189/jlb.0907611

10.1038/bjc.2013.32

10.2174/156800910790980197

10.1038/nm.2250

10.1111/cas.12015

10.1172/JCI59643

10.1002/stem.185

10.1073/pnas.1106645108

10.1038/nature08534

10.1158/1078-0432.CCR-12-2788

10.1016/j.intimp.2011.01.003

10.1016/j.intimp.2011.03.003

10.4049/jimmunol.0802740

10.1002/eji.201040895

10.1038/nrc2618

10.1158/1078-0432.CCR-12-1108

10.1182/blood-2001-11-0097

10.1038/ni.2467

10.1084/jem.20092140

10.1172/JCI32282

10.1182/blood-2011-02-339911

10.1038/ni.1920

10.1038/nri3088

10.1016/j.ccr.2013.01.008

10.1186/1479-5876-9-177

10.1038/nature10138

10.1158/1535-7163.MCT-09-0280

10.1111/j.1349-7006.2010.01772.x

10.1002/mnfr.201200610

10.1245/s10434-011-1609-3

Ohno S, 2004, Correlation of histological localization of tumor‐associated macrophages with clinicopathological features in endometrial cancer, Anticancer Res, 24, 3335

10.1016/j.ygyno.2007.12.033

10.1158/1078-0432.CCR-06-2073

10.1111/j.1572-0241.2004.30733.x

Shimura S, 2000, Reduced infiltration of tumor‐associated macrophages in human prostate cancer: association with cancer progression, Cancer Res, 60, 5857

10.1200/JCO.2007.15.6521

10.1136/jclinpath-2011-200355

Leek RD, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res, 56, 4625

10.1677/ERC-08-0036

10.3892/or_00000873

10.1046/j.1442-2042.2000.00190.x

10.1002/cncr.26143

Makitie T, 2001, Tumor‐infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma, Invest Ophthalmol Vis Sci, 42, 1414

10.1200/JCO.2011.40.9169

10.1016/j.ajpath.2011.05.034

10.1056/NEJMoa0905680

10.1200/JCO.2007.12.8298

10.1186/1479-5876-5-62

10.1159/000346196

10.1371/journal.pone.0059771

10.1111/j.1349-7006.2010.01614.x

10.1016/j.jss.2009.05.026

10.1111/j.1349-7006.2012.02411.x

10.1002/ijc.27403

10.1371/journal.pone.0021874

10.1097/JTO.0b013e3182745968

10.1111/j.1600-0714.2012.01127.x

10.1002/ijc.28335

10.1158/1078-0432.CCR-10-2047

10.2353/ajpath.2009.081037

10.1200/JCO.2008.19.9919

10.1167/iovs.10-5979

10.1111/j.1365-2559.2011.04096.x

10.1007/s00428-011-1140-8

10.3324/haematol.2011.055459

10.1182/blood-2012-04-421057

10.1182/blood-2009-11-253260

10.1007/s00277-012-1652-6

Thông tin
Thông tin xuất bản

Cancer Science

Tập 105 Số 1

1-8

Thông tin tác giả